-
公开(公告)号：US11827719B2
公开(公告)日：2023-11-28
申请号：US16841527
申请日：2020-04-06
Inventor： Hirohisa Saito , Kenji Matsumoto , Hideaki Morita , Go Ichien , Yasuhiko Koezuka , Kimishige Ishizaka
CPC classification number: C07K16/4291 , A61P37/08
Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.
-
2.发明申请公开(公告)号：US20200231705A1
公开(公告)日：2020-07-23
申请号：US16841527
申请日：2020-04-06
Inventor： Hirohisa Saito , Kenji Matsumoto , Hideaki Morita , Go Ichien , Yasuhiko Koezuka , Kimishige Ishizaka
Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof
-
公开(公告)号：US20170202210A1
公开(公告)日：2017-07-20
申请号：US15312675
申请日：2015-02-24
Inventor： Tohru TANAKA , Motowo NAKAJIMA , Urara OTA , Hidenori ITO , Ko RII
IPC: A01N1/02
CPC classification number: A01N1/0226 , A01N1/02
Abstract: Provided is an organ preservation solution for use in transplantation, which is capable of effectively preventing the occurrence of ischemia-reperfusion injury. Prepared is an organ preservation solution comprising a mixture of the following components: (a) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, and D-glucose; (b) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, glycine, and D-glucose; (c) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, and D-glucose; or (d) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, an iron compound, and D-glucose.
-
公开(公告)号：US20250101431A1
公开(公告)日：2025-03-27
申请号：US18473936
申请日：2023-09-25
Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT , HIROSHIMA UNIVERSITY , DAIICHI SANKYO COMPANY, LIMITED
Inventor： Go Tajima , Satoshi OKADA , Miyuki TSUMURA
IPC: C12N15/113
Abstract: The present invention provides a novel antisense oligonucleotide and a composition for preventing or treating glycogen storage disease type Ia. The present invention provides an antisense oligonucleotide which hybridizes with a pre-mRNA sequence derived from a region including at least one of a base at position 42911000, a base at position 42911004, and a base at position 42911005 in a base sequence of human chromosome 17 of GRCh38/hg38 and has activity to inhibit aberrant splicing of pre-mRNA of c.648G>T variant G6PC.
-
公开(公告)号：US20240335480A1
公开(公告)日：2024-10-10
申请号：US18579100
申请日：2022-07-14
Applicant: Astellas Pharma Inc. , OSAKA UNIVERSITY , National Center for Child Health and Development
Inventor： Kenichiro SHIMATANI , Hiromu SATO , Masao SASAI , Yoshiki SAWA , Atsuhiro SAITO , Shigeru MIYAGAWA
IPC: A61K35/545 , A61K35/44 , C12N5/071
CPC classification number: A61K35/545 , A61K35/44 , C12N5/069 , C12N2506/02 , C12N2513/00
Abstract: An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.
-
Patent Agency Ranking
公开(公告)号：US20230020917A1
公开(公告)日：2023-01-19
申请号：US17786259
申请日：2020-12-18
Inventor： Ayako AYABE , Takanori HASEGAWA , Kenji MATSUMOTO , Hideaki MORITA
Abstract: The present invention provides highly effective and safe means capable of preventing or treating an egg allergy in infants. An oral immunotolerance agent or a food composition for preventing or treating an egg allergy according to the present invention contains a degraded product of heat-denatured egg white with an aspartic protease (e.g. pepsin) or a metal protease (e.g. thermolysin).
-
公开(公告)号：US20220249417A1
公开(公告)日：2022-08-11
申请号：US17682413
申请日：2022-02-28
Inventor： Tohru Tanaka , Hidenori Ito , Ko Rii
IPC: A61K31/197 , A61K33/26 , C07K16/28 , A61K33/24
Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.
-
公开(公告)号：US11266619B2
公开(公告)日：2022-03-08
申请号：US16651238
申请日：2018-11-28
Inventor： Tohru Tanaka , Hidenori Ito , Ko Rii
Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.
-
公开(公告)号：US20170191033A1
公开(公告)日：2017-07-06
申请号：US15502321
申请日：2015-08-07
Inventor： Noriyuki Azuma , Taku Tanaka , Tadashi Yokoi
CPC classification number: C12N5/0621 , A61K35/30 , A61L27/00 , A61P27/06 , C12N15/09 , C12N2501/13 , C12N2506/02 , C12N2506/08 , C12N2506/45 , C12Q1/02 , C12Q1/6876 , C12Q2600/136 , C12Q2600/158 , G01N33/5058
Abstract: An object of the present invention is to provide a method of inducing pluripotent stem cells to differentiate into clinically applicable retinal ganglion cells.The present invention provides a method for inducing pluripotent stem cells to differentiate into retinal ganglion cells that can be used for clinical application. Such method is a method for producing retinal ganglion cells with elongated axons comprising the following steps: (a) a step of inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) a step of inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) a step of allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).
-
公开(公告)号：US09399029B2
公开(公告)日：2016-07-26
申请号：US14413151
申请日：2013-07-03
Inventor： Tohru Tanaka , Motowo Nakajima , Fuminori Abe , Naomi Haga , Kiwamu Takahashi , Hidenori Ito , Ko Rii
IPC: A61K31/197 , A61K33/26 , C12N5/0784 , A61K38/19 , A61K31/194 , A61K38/40
CPC classification number: A61K31/197 , A61K31/194 , A61K33/26 , A61K38/193 , A61K38/40 , C12N5/064 , C12N2500/24 , C12N2501/052 , C12N2501/22 , C12N2501/2304 , A61K2300/00
Abstract: An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
Abstract translation: 本发明的目的是提供适用于免疫疾病的治疗的调节性树突状细胞诱导剂以及免疫耐受诱导剂，例如过敏性疾病的预防和/或治疗剂以及预防和/或治疗剂 对于自身免疫性疾病，两者都是安全的，并且具有与常规药物不同的作用机制。 作为实现上述目的的方法，制备包含5-氨基乙酰丙酸（ALA）或其衍生物或5-ALA或其衍生物和铁化合物的盐作为活性成分的免疫耐受诱导剂。 ALA的优选实例可以包括ALA和各种酯，例如ALA的甲酯，乙酯，丙酯，丁酯和戊酯，以及它们的盐酸盐，磷酸盐和硫酸盐。 铁化合物的优选实例可包括柠檬酸亚铁钠。
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.023 seconds)
